Man Asks Court To Order FDA To Respond To Petition To Update SSRI Warning Labels
WASHINGTON, D.C. — A professor researching the risk of sexual dysfunction after stopping selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) drugs filed a complaint asking a District of...To view the full article, register now.
Already a subscriber? Click here to view full article